Human Integrin alpha V beta 5 (ITGAV&ITGB5) Heterodimer Protein, His Tag&Tag Free

Source : 

Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free (IT5-H52W5) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 24 - Asn 719 (ITGB5) (Accession # NP_002201.1 (ITGAV) & NP_002204.2 (ITGB5)).

 

Molecule : Integrin alpha V beta 5

 

Synonyms : Integrin alpha V beta 5,ITGAV&ITGB5

 

Format : Powder

 

Category : Bio-Markers & CD Antigens

 

Accession : NP_002201.1 (ITGAV) & NP_002204.2 (ITGB5)

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 112.9 kDa (ITGAV) & 81.9 kDa (ITGB5)

 

Characteristics :

Human ITGAV&ITGB5 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB5, has a calculated MW of 112.9 kDa (ITGAV) and 81.9 kDa (ITGB5). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : 50 mM Tris, 150 mM NaCl, pH7.5

 

Description :

Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.

 

References :

(1) Suzuki, S. et al., 1990,Proc. Natl. Acad. Sci. USA 87:5354-8.
(2) Memmo, L.M. and P. McKeown-Longo, 1998, J. Cell Sci.111:425-33.
(3) Desgrosellier, J.S. and D.A. Cheresh, 2010, Nat. Rev. Cancer 10:9-22.
(4) Luzina, I.G. et al., 2009, Arthritis Rheum. 60:1530-9.